RAD011 ( DrugBank: - )


1 disease
告示番号疾患名(ページ内リンク)臨床試験数
193プラダー・ウィリ症候群3

193. プラダー・ウィリ症候群


臨床試験数 : 113 薬物数 : 111 - (DrugBank : 26) / 標的遺伝子数 : 48 - 標的パスウェイ数 : 102
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT05387798
(ClinicalTrials.gov)
January 202317/5/2022A Phase 3 Extension Study of RAD011 (Cannabidiol Oral Solution) in Patients With Prader-Willi SyndromeA Phase 3, Open-label Extension Study to Assess the Safety, Tolerability, and Efficacy of RAD011 (Cannabidiol Oral Solution) in Patients With Prader-Willi SyndromePrader-Willi SyndromeDrug: RAD011Radius Pharmaceuticals, Inc.NULLWithdrawn8 Years65 YearsAll0Phase 3NULL
2NCT05098509
(ClinicalTrials.gov)
April 13, 202222/9/2021A Phase 2/3 Study of RAD011 (Cannabidiol Oral Solution) for the Treatment of Patients With Prader-Willi SyndromeA Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study of RAD011 (Cannabidiol Oral Solution) for the Treatment of Patients With Prader- Willi SyndromePrader-Willi SyndromeDrug: RAD011;Drug: PlaceboRadius Pharmaceuticals, Inc.NULLTerminated8 Years65 YearsAll7Phase 2/Phase 3United States
3EUCTR2021-005331-23-SE
(EUCTR)
18/05/2022A Study of RAD011 (Cannabidiol Oral Solution) for the Treatment of Patients with Prader-Willi SyndromeA Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study of RAD011 (Cannabidiol Oral Solution) for the Treatment of Patients with Prader-Willi Syndrome Hyperphagia related behavior associated with Prader-Willi Syndrome
MedDRA version: 20.0;Level: PT;Classification code 10020710;Term: Hyperphagia;System Organ Class: 10027433 - Metabolism and nutrition disorders;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
Product Name: RAD011
Product Code: RAD011
INN or Proposed INN: Cannabidiol
Radius Pharmaceuticals, Inc.NULLNot RecruitingFemale: yes
Male: yes
220Phase 2;Phase 3France;United States;Canada;Belgium;Spain;Australia;United Kingdom;Italy;Sweden